Antag Therapeutics Secures $84M to Advance GIPR Antagonist AT-7687 with Novo Holdings Support
Antag Therapeutics, a Danish startup, has successfully raised €80 million (approximately $84 million) in Series A financing, a significant milestone that highlights the investor confidence it has garnered from prominent ventures such as Versant Ventures and Novo Holdings[1][2]. The funding is directed towards advancing its lead candidate, AT-7687, a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist intended for obesity treatment. This innovative treatment aims to augment the weight loss effects of co-administered therapies, such as GLP-1 medicines, while potentially reducing side effects like nausea and vomiting associated with current treatments in the market[2][3]. Antag's strategy, set against a backdrop of robust scientific roots at the University of Copenhagen, plans to initiate clinical trials by early 2025, potentially reshaping the landscape of obesity treatments[3].
References
Explore Further
What are the potential advantages of AT-7687 over existing obesity treatments like those offered by Novo Nordisk?
How does the strategic support from Versant Ventures and Novo Holdings benefit Antag Therapeutics in advancing AT-7687?
What challenges did Amgen's MariTide face in the market, and how might Antag avoid them with AT-7687?
Why does Antag Therapeutics see potential in combining AT-7687 with GLP-1-based therapies?
What are the expected outcomes of the Phase 1 clinical trials for AT-7687 set to begin in 2025?